Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRVNASDAQ:ALECNASDAQ:CGENNASDAQ:GALT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.30+0.4%$1.23$1.05▼$10.16$40.45M1.64268,592 shs125,785 shsALECAlector$1.48-1.7%$1.35$0.87▼$6.78$150.99M0.74839,031 shs233,289 shsCGENCompugen$1.78+2.3%$1.55$1.13▼$2.66$157.06M2.57366,765 shs94,601 shsGALTGalectin Therapeutics$2.16-0.7%$1.64$0.73▼$3.90$137.98M0.7412,302 shs239,497 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics0.00%+7.92%+3.60%-14.24%-78.91%ALECAlector0.00%-0.34%+4.61%+44.61%-66.55%CGENCompugen0.00%+7.23%+4.09%+35.88%+6.59%GALTGalectin Therapeutics0.00%-7.51%+65.77%+63.26%+0.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics2.6221 of 5 stars3.52.00.00.01.13.30.6ALECAlector3.7429 of 5 stars3.13.00.04.50.62.50.0CGENCompugen1.5607 of 5 stars3.53.00.00.01.10.00.0GALTGalectin Therapeutics1.6587 of 5 stars3.50.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,267.90% UpsideALECAlector 2.14Hold$4.00171.19% UpsideCGENCompugen 3.00Buy$4.00124.72% UpsideGALTGalectin Therapeutics 3.00Buy$6.00178.42% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, CGEN, ALEC, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AALECAlector$100.56M1.47N/AN/A$1.29 per share1.14CGENCompugen$27.86M5.70N/AN/A$0.62 per share2.87GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)ALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)CGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)Latest ACRV, CGEN, ALEC, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AALECAlectorN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A11.1711.17ALECAlector0.103.343.34CGENCompugenN/A5.095.09GALTGalectin TherapeuticsN/A0.080.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%ALECAlector85.83%CGENCompugen12.22%GALTGalectin Therapeutics11.68%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics11.90%ALECAlector9.10%CGENCompugen9.50%GALTGalectin Therapeutics50.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million27.62 millionNot OptionableALECAlector27099.99 million90.89 millionOptionableCGENCompugen7089.24 million80.76 millionOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableACRV, CGEN, ALEC, and GALT HeadlinesRecent News About These CompaniesGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average - Here's What HappenedJuly 1, 2025 | marketbeat.comGalectin Therapeutics Inc. (GALT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street ZenJune 21, 2025 | marketbeat.comGalectin Therapeutics Inc. Common Stock (GALT)June 20, 2025 | nasdaq.comGalectin Therapeutics Inc.June 20, 2025 | wsj.comWhat is HC Wainwright's Estimate for GALT Q2 Earnings?June 19, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT)June 17, 2025 | marketbeat.comGalectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension TreatmentJune 11, 2025 | nasdaq.comGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal HypertensionJune 10, 2025 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business UpdateMay 17, 2025 | seekingalpha.comGalectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 CongressMay 12, 2025 | globenewswire.comWhy Galectin Therapeutics Inc.’s (GALT) Stock Is Up 14.71%May 7, 2025 | aaii.comAWhy Galectin Therapeutics Inc.’s (GALT) Stock Is Down 5.07%April 22, 2025 | aaii.comAGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 CongressApril 15, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)April 2, 2025 | markets.businessinsider.comGalectin Therapeutics reports FY24 EPS (76c) vs (74c) last yearApril 2, 2025 | markets.businessinsider.comWhy Galectin Therapeutics Inc.’s (GALT) Stock Is Down 20.00%March 31, 2025 | aaii.comAGalectin Therapeutics Reports 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comWhile insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownershipMarch 8, 2025 | finance.yahoo.comGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE TrialFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics’ belapectin shows reduction in new varicesFebruary 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, CGEN, ALEC, and GALT Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.30 +0.01 (+0.39%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$1.30 0.00 (0.00%) As of 07/3/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Alector NASDAQ:ALEC$1.48 -0.03 (-1.67%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$1.48 0.00 (0.00%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Compugen NASDAQ:CGEN$1.78 +0.04 (+2.30%) Closing price 07/3/2025 02:20 PM EasternExtended Trading$1.79 +0.01 (+0.51%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Galectin Therapeutics NASDAQ:GALT$2.15 -0.02 (-0.69%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.15 0.00 (-0.23%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
